•
Dec 31, 2020
Liquidia Q4 2020 Earnings Report
Reported full-year financial results and provided a corporate update.
Key Takeaways
Liquidia Corporation reported its full-year 2020 financial results, highlighting the closure of the RareGen, LLC acquisition, executive team changes, and plans to respond to the LIQ861 CRL. The company is also focused on improving its balance sheet and cash spend, expecting positive contributions from Treprostinil Injection sales.
Closed the acquisition and integration of RareGen, LLC, now known as Liquidia PAH, LLC, providing a commercial presence in PAH.
Confirmed plan to submit response to LIQ861 CRL in mid-2021.
Strengthened intellectual property tied to inhaled dry powder treprostinil with the issuance of patent No. 10,898,494.
Reduced net annual cash spending to strengthen financial position by more than 40% compared to 2020 spending.